BACKGROUND
Brain metastases are a common and serious consequence for patients with renal cell carcinoma. This study aimed to determine if survival has changed since the introduction of current therapies, identify prognostic factors, update the prognostic index (the Renal Graded Prognostic Assessment [GPA]) in the conte...
P. Sperduto, F. Johri, Hany Soliman et al.· The Lancet Oncology· 0 citations
The findings suggest that the combination of tocilizumab, atezolizumab, and FSRT was safe and well tolerated in patients with rGBM but did not achieve the pre-specified efficacy outcome.
Stephen J. Bagley, Mei-Yin C. Polley, R. Kotecha et al.· International Journal of Rad...· 0 citations
Postoperative radiotherapy is commonly used after resection of brain metastases, but durable local control with a low rate of adverse events (AEs) remains challenging. This systematic review summarizes outcomes and AEs of postoperative stereotactic interventional radiotherapy (S-IRT; brachytherapy) for resected brain m...
M. Bilski, F. Mastroleo, I. Baranowska et al.· La radiologia medica· 0 citations
This review summarizes the current biologic and clinical framework of BM, including molecular divergence from the primary tumor, the evolution of prognostic models, and the growing role of brain-specific risk stratification in treatment planning.
Z. Sarfraz, R. Kotecha, Arun Maharaj et al.· Neurotherapeutics· 1 citation
SBRT for rib metastases from prostate cancer was associated with high LC, pain relief, and low observed toxicity in this retrospective real-world cohort, and GTV-only contouring may be feasible in carefully selected patients staged and planned with PSMA-PET/CT.
M. Bilski, F. Mastroleo, I. Banaszek et al.· Therapeutic Advances in Medi...· 0 citations
In this prospective registry, resection followed by GammaTile brachytherapy achieved excellent local control, and manageable toxicity in newly diagnosed BM, supporting that GammaTile brachytherapy is a promising strategy for large or symptomatic BM.
Ruchit P. Jain, Z. Sarfraz, Mukesh Roy et al.· Neuro-Oncology Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.